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ABSTRACT:  This  article reports the results obtained from a study of the usefulness of 
Saussurea Lappa on the treatment of Ichaemic Heart Diseases. 
 
INTRODUCTION 
 
In the present advanced and industrialized 
society, the three causes of death in order of 
frequency are Ischaemic Heart Disease 
(IHD), Diabetes  mellitus and 
Cerebrovascular accidents.  The prevalence 
of IHD has been reported to be as high as 
50% among diabetes as per date of 
American Diabetic Associations 
(Vttilingam, K. et al, 1964).  Major risk 
factors for IHD are diabetes mellitus and 
atherosclerosis (Kanne et al, 1977).  The 
control of diabetes and hyperlipidemia is 
always useful in the prevention and 
treatment of IHD.  The present work is an 
attempt to find out a safe, simple and 
reliable drug for the treatment of IHD in 
diabetic patients. 
 
The herbal drug Kushtha (Saussurea lappa) 
has been widely referred by many classics of 
Indian Medicine (Sanghita as well as 
Chikitsa granthas).  The drug is indicated in 
the disease like skin, obesity, heart, 
madhumeha (diabetes), svaskas and 
aphrodisiac tonic.  This drug has been 
claimed to be antiallergic (Chopra, R.N., 
1930).  Antibacterial (Bhavasar, G.C., 1965) 
and Antihistaminic (Dhosr, M.L., et al., 
1980 and Gafar, M.A., et al., 1975).   
Recently the drug have proved to be a 
promising antidiabetic and hypolipidaemic 
agent (Upadhyay, O.P., Ojha, J.K. and 
Bajpai, H.S., 1983).  So the present work 
has been undertaken and drug kushtha 
(S.lappa) has been selected for further study 
to establish its effect in patients of IHD for 
comparison a known vasodilator drug 
segontin (Prenylominelactate 500 mg) has 
been taken. 
 
MATERIALS AND METHODS 
 
The present study induced 45 patients 
suffering from IHD the cases were selected 
from those attending the diabetic clinic, S.S. 
Hospital, I.M.S., B.H.U., Varanasi.  The 
diagnosis of diabetes mellitus was made by 
the standard oral glucose tolerance test 
(National Diabetic Data) and IHD on 
clinical grounds.  The cases were divided 
into three groups (n=15 in each), group I 
was treated with Kushtha alone, group II 
was treated with  Kushtha + Segontin and 
group III was received segontin alone. 
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-  Aqueous extract of Kushtha prepared 
from B.H.U.  Pharmacy was 
administered orally in the dose of 
1500 mg in three divided dosage i.e 
500 mg thrice; Tab. Segontin 
(Prenylamine lactate 500 mg) was 
administered orally in the dose of 
one or two Tab. Thrice a day. 
 
-  The drug were started in all the three 
groups after control of diabetes.   
Following parameters observed 
during this clinical trial – 
 
a.  Detailed history and clinical 
examination. 
 
b.  Laboratory investigations included 
biochemical assay of blood sugar 
(Harding methods by Astoor and 
Kings, 1954), Serum Cholesterol 
(Bloor, Richard, Alless 1922) and 
serum triglycerides (micromethods 
of van Handle Zillersmith, 1957). 
 
c.  Electro-cardiogram (ECG) 
recording. 
 
Follow-up clinical examination, bio 
chemical investigations and ECG was done 
every month for a period of 4 months.   
Overall assessment of results was done by 
categorizing the patients into three groups, 
according to the response of therapies. 
 
1.  Significant Response  : Appreciable 
improvement in clinical symptoms, 
control of diabetes mellitus and other 
biochemical parameters and ECG 
changes. 
 
2.  Moderate Response  :  
Improvement in clinical symptoms, bio-
chemical parameters and ECG. 
 
3.  No Response     :  No 
significant response in clinical 
symptoms bio chemical parameters as 
well as ECG changes. 
 
RESULTS AND DISCUSSION 
 
Among  the patients who were studied, 32 
were males and 13 were females of age 30 – 
65 years.  It is evident from the table No.1 
that males have been more (71.12%) 
affected with IHD. Similarly the age group 
of 40 –  60 years are prone to get this 
disease.  These observation showed the 
conformity with the observation of William 
B. and Kannel, M.D. (1974). 
 
Before the treatment there were 30 cases 
who showed precardial pain, dysponea and 
palpitation by walking fast or walking uphill 
or after full stomach.  The rest 15 cases were 
having symptoms even of slow or walking at 
an average speed usually within 300 yards.  
After 4 months of treatment in group I, the 
response was significant in 1 case, moderate 
in 7 cases and there was no response in 7 
cases.   
 
Similarly in the group II (Kushtha + 
Segontin) significant response was observed 
in 7 cases, moderate in 6 cases and no 
response in two cases.  Whereas in group III 
that is on segontin alone the response was 
significant in 2 cases, moderate in 11 cases 
and no response in 2 cases.  These 
observations clearly show the effectiveness 
of the combined group i.e II (Table No.2). 
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TABLE – 1 
 
Age & Sex Distribution of the Patients 
 
Age Group  
in years 
Sex 
Male (No. of cases)  Female (No. of cases) 
40 – 50  09  04 
50 – 60  16  06 
60 – 70  07  03 
TOTAL  32  13 
 
 
TABLE – 2 
 
Response in Clinical Symptoms after 4 Month Treatment 
 
S. 
No. 
Group  Significant response  Moderate response  No Response 
No. of 
cases 
%  No. of 
cases 
%  No. of 
cases 
% 
I  Kushtha  01  6.8  07  46.6  07  46.6 
II  Kushtha + Segontin  07  46.6  06  40.0  02  13.3 
III  Segontin  02  13.4  11  73.2  02  13.4 
 
TABLE – 3 
 
Changes in Serum Cholesterol Levels after 4 Months Treatment  
(Mean + SE value of serum cholesterol in mg%) 
 
S. No.  Group  S. cholesterol 
before treatment 
in mg% 
S. cholesterol after 
treatment in mg%  
Changes in 4 
months 
I  Kushtha  440  7.66  280  7.50  160  11.22 
t = 14.26* 
II  Kushtha + Segontin  400  10.52  240.3  5.68  138.67  10.66 
t = 13.001* 
III  Segontin  430  6.84  360.67  9.68  63.33  9.33  
t = 6.67* 
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TABLE – 4 
 
Reduction in Serum Triglycerides after 4 Months Treatment 
(Mean  SE value of serum triglycerides in mg%) 
 
S.  
No. 
 GROUP  S.T.G. before 
treatment in 
mg% 
S.T.G. after 
treatment in 
mg% 
Reduction    
4 months  
I  Kushtha  300  6.77  180  6.40  120  14.21  
t = 14.29 * 
II  Kushtha + Segontin  280  9.21  178  5.79  96.67  8.88 
t = 10.89*  
III  Segontin  290  6.70  240  5.68  48.67  7.30 
t = 6.67* 
          
* p/0.001 significant at 0.01% level of probability. 
 
Table 3 and 4 represents serum cholesterol 
and triglycerides value of all 45 cases of 
IHD before and after treatment.  Drug 
theraphy of 4 months reduced the value of S. 
cholesterol to 280   7.50 mg % from a 
pretreatment value of 440   7.66 mg% in 
group I, 240  5.68 mg% from 400  10.52 
mg% in group II and 360  10.68 mg% from 
430    6.84 mg% in group III.  Serum 
triglycerides value was also reduced to 180  
6.40 mg% from 300  6.77, 178  5.79 from 
280  9.29 mg% and 240  5.68 from 290  
6.70 mg% respectively in group I, II and III.  
When statically evaluated, the reduction in 
S. Cholesterol and S. triglycerides was 
significant (n<0.009).  While comparing 
three groups the reduction was highly 
significant (P<0.001) in group II.  These 
findings were similar with our previous 
experimental study. 
 
Table 5 showed the ECG changes in all 45 
patients.  Before the treatment, there was ST 
depression and T wave inversion in different 
leads according to the site of lesion.  After 
therapy for 4 months 26 cases showed 
significant response, 10 cases moderate 
response and the remaining 9 cases showed 
no response (Table 6).  While comparing the 
ECG improved  in all three groups, 80% 
cases of combined group II showed 
significant response.  As an illustration the 
ECG on one case is being given. 
 
Fig.5 showed ECG changes (ST depression 
and T wave inversion in all leads) before the 
treatment.  After the treatment with Kushtha 
+ segontin there was reversion of ST 
depression and T wave in all leads towards 
normalcy. 
 
As regards the dose it was observed the few 
patient of segontin group required maximum 
dose of 3 tab. Thrice a day whereas in 
combination with Kushtha the dose of 
segontin was only 1 tab. Twice a day.  Side 
effects, i.e., G.I.T. disturbances headache, 
dizziness, nervousness etc. were noted in 36 
patients of segontin alone treated group III, 
while in combined group no major side 
effects was noted except mile sedation and 
lassitude this may be because of small of 
drug of segontin.  Similarly in group I, 
Kushtha treated only one case observed with 
the symptom of diarrhea (Table 7). 
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and ECG, significant improvement was 
observed in the 65% cases of combined 
group.  These results suggested that therapy 
with the lipid lowering drug Kushtha also 
improves coronary circulation and 
myocardial functions. 
 
TABLE – 5 
Pattern of Positive ECG Findings Observed in Patients of IHD 
 
ECG Findings  No. of Patients  Percentage 
ST Segment depression and T wave 
inversion in L1, aVL and V4 – V6 
 
13  28.6 
ST segment depression and T wave 
inversion in Ln, Lm and aVF 
 
11  24.4 
ST depression and T wave inversion in 
L1, Ln, aVL, aVF and V4 – V6 
 
16  35.6 
ST depression and T wave inversion in 
V1 – V3 
 
05  11.1 
Total  45   
 
 
TABLE – 6 
Effect of 4 Months Treatment on E.C.G. in 45 Cases. 
 
S. 
No. 
Group  Significant response *  Moderate response **  No response *** 
I  Kushtha  04  26.7  06  40.0  05  33.3 
II  Kushtha + Segontin  12  80.0  02  13.4  01  6.6 
III  Segontin  10  66.6  02  13.4  03  20.0 
 
*     ST segment depression and T inversion were reverted. 
**   Progressive improvements in ST depression revert to normal although lead T inversion was  
       recorded. 
*** No significant changes. 
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Table – 7 
 
Side Effect in the Patients of Different Group 
 
Side Effects  Segontin  
No. of Pts. 
Segontin + Kushtha  
No. of Pts. 
Kushtha 
No. of Pts. 
Diarrhea  2  1  1 
Sedation  1  2  * 
Tension  1  *  * 
Headache  3  *  * 
Flushing  2  *  * 
Nervousness  1  1  * 
Lassitude  2  4  * 
Lethargy  3  *  * 
Total  36  8  1 
 
SUMMARY AND CONCLUSION 
 
This communication described a preliminary 
clinical trial of a new drug Kushtha 
(Saussurea lappa,  Clarke)  on the cases of 
IHD.  The drug was used both individually 
and in combination with Segontin.  To 
evaluate the response of the drug, the 
clinical features, ECG and bio chemical 
parameters were recorded.  The response 
was graded as significant, moderate and no 
response.  After the treatment for four 
months significant improvement in clinical 
and biochemical parameters of Kushtha, 
Segontin group.  A part from that more 
marked improvement in ECG observed in 
the group II where ECG comes to normal.  It 
can be interpreted: 
 
1.  that the combination of Kushtha and 
Segontin is more effective and suitable 
without occurrence of any major side 
effects. 
2.  the dose of segontin could be reduced in 
combined drug therapy (group II) in 
comparison to sengontin group.  The 
side effects were also less in combined 
group. 
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